Bioxyne Ltd – Sale of HI-164OV Hunter Immunology Pty Ltd
Please find the ASX announcement here.
Bioxyne divests its COPD related HI-164OV research program for up to $1.56 million.
Please find the ASX announcement here.
Bioxyne divests its COPD related HI-164OV research program for up to $1.56 million.